Novavax, a developer of a COVID-19 vaccine, said it signed a deal to downsize its presence in the Washington, D.C., suburbs to focus on research and development efforts in a more cost-effective manner after a major investor slammed the company for underperformance and suggested it put itself up for sale.
Novavax to transfer lease at Maryland property to AstraZeneca in money-saving move
Deal follows large shareholder recommending potential sale of Gaithersburg-based vaccine maker
CoStar News
October 22, 2025 | 8:11 P.M.
RELATED ARTICLES
This news story is available exclusively to CoStar subscribers.
Watch the video to learn how you can access industry leading CRE news and the data analytics you need to drive success.
This news story is available exclusively to CoStar subscribers.
Ready to Learn More?
Sign Up For a Personalized Demo.
Sign Up For a Demo To Learn More.
Already A Subscriber? Sign In
IN THIS ARTICLE
- Properties
- Bio at 700 QO
700 Quince Orchard Rd, Gaithersburg, MD
- Companies
- Novavax
Manufacturing
- AstraZeneca
Manufacturing
- Alexandria Real Estate Equities, Inc.
Real Estate
- Contacts
- HIMANSHU SHAH
Founder, President, CIO, Shah Capital Fund LP
- John Jacobs
President & CEO, Novavax